Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Tanaka, Yoshiya; Kameda, Hideto; Saito, Kazuyoshi; Kaneko, Yuko; Tanaka, Eiichi; Yasuda, Shinsuke; Tamura, Naoto; Fujio, Keishi; Fujii, Tomoyuki; Kojima, Toshihisa; Anzai, Tomohiro; Hamada, Chikuma; Fujino, Yoshihisa; Matsuda, Shinya; Kohsaka, Hitoshi

doi:10.1186/s13075-018-1647-3

Cited by 13 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty‐one studies reported utility scores of RA patients 22‐24,34‐42,45,47‐63,65 . The pooled mean EQ‐5D score was 0.66 (95% CI 0.63‐0.69) with high heterogeneity I 2 = 99.65% (Figure 2A).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

2021

View full text Add to dashboard Cite

Introduction Region‐specific health‐related quality of life (HRQoL) scores or utility values are representative and pivotal for economic evaluations as they are influenced by the value judgment of the local population. This study systematically reviewed and pooled EuroQoL‐5 Dimension (EQ‐5D) utility scores of rheumatoid arthritis (RA) across primary studies from Asia. Methods Studies reporting EQ‐5D utility scores among adult RA patients from Asian countries were systematically searched in PubMed‐Medline, Scopus and Embase since inception through February 2020. Selected studies were systematically reviewed and study quality assessment was performed. Meta‐analysis was performed using a random‐effect model with subgroup and meta‐regression analysis to explore heterogeneity. Results Among 1391 searched articles, 37 studies with 31 983 participants were systematically reviewed and meta‐analysis was conducted among 31 studies. The pooled EQ‐5D scores and EQ‐5D visual analog score were 0.66 (95% CI 0.63‐0.69, I2 = 99.65%) and 61.21 (50.73‐71.69, I2 = 99.56%) respectively with high heterogeneity. For RA patients with no, low, moderate and high disease activity based on Disease Activity Score (DAS)‐28, the pooled EQ‐5D scores were 0.78 (0.65‐0.90), 0.73 (0.65‐0.80), 0.53 (0.32‐ 0.74), and 0.47 (0.32‐0.62), respectively. On meta‐regression, age of patients (P < .05) was positively associated and use of glucocorticoids (P < .05) was inversely associated with utility values. Conclusion Lower EQ‐5D scores were associated with severe disease activity, increasing age and female gender among RA patients. The study provides pooled EQ‐5D scores for RA patients that are useful inputs for cost‐utility studies in Asia.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Thirty-one studies reported utility scores of RA patie nts. [22][23][24][34][35][36][37][38][39][40][41][42]45,[47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63]65 The pooled mean EQ-5D score was 0.66 (95% CI 0.63-0.69) with high heterogeneity I 2 = 99.65% (Figure 2A).…”

Section: Overall Pooling Of Eq-5dmentioning

confidence: 99%

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

2021

View full text Add to dashboard Cite

show abstract

“…The symptoms of sleep disturbance and fatigue are significantly correlated with diminished patient quality of life. Moreover, TCZ improved patient-reported outcomes according to the modified Health Assessment Questionnaire (mHAQ) including reduced morning stiffness and favorable EQ-5D responses [21,22]; it also ameliorated work impairment [23].…”

Section: Efficacy Of the Il-6 Inhibitor In Ramentioning

confidence: 99%

IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review

Ogata

Kato

Higa

et al. 2019

Modern Rheumatology

160

124

View full text Add to dashboard Cite

Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from all over the world based on its first decade of use. Although the overall efficacy and safety profiles of TCZ are similar to those of tumor necrosis factor (TNF) inhibitors, TCZ displays certain differences. The most notable advantage of TCZ is its usefulness as a monotherapy. Additionally, TCZ is favorable in the improvement of systemic inflammatory symptoms such as anemia and fatigue. The low immunogenicity of TCZ contributes favorably to long-term drug retention. Due to frequent relapse after TCZ cessation, TCZ use should be tapered beyond remission. During TCZ therapy, C-reactive protein (CRP) is unable to recognize disease activity and the severity of infection. The most common adverse events (AEs) are infection and abnormalities in laboratory findings including dyslipidemia, neutropenia, thrombocytopenia, and abnormality of liver enzymes. TCZ obscures the symptoms of infection. Therefore, stealth infections without obvious CRP elevation can sometimes cause severe damage to patients. Lower intestinal perforation is an uncommon but serious AE in TCZ therapy. Further clinical investigations will continue to refine the IL-6 inhibitory strategy.

show abstract

“…Improvements of a similar magnitude for this WPAI component have been reported for baricitinib, upadacitinib, and filgotinib in patients with RA [ 33 – 37 ]. A study of work productivity for RA patients receiving the anti-IL-6 receptor antibody tocilizumab also showed responses of a similar magnitude to peficitinib for improvements in daily activity impairment [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on patient- and physician-reported outcomes in Asian patients with RA and an inadequate response to prior disease-modifying antirheumatic drugs (DMARDs). Methods Patients from two randomized, placebo-controlled, double-blind, phase 3 trials (RAJ3 and RAJ4) received once-daily peficitinib 100 mg, peficitinib 150 mg, or placebo, alone or in combination with DMARDs (RAJ3), or in combination with methotrexate (RAJ4). Mean changes in Work Productivity and Activity Impairment (WPAI) questionnaire domain scores from baseline, and percentages of patients achieving minimal clinically important differences (MCIDs) for patient- and physician-reported outcomes (WPAI, Health Assessment Questionnaire – Disability Index [HAQ-DI], and Subject’s Global Assessment of Pain [SGAP]), and Physician’s Global Assessment of disease activity (PGA) were evaluated at weeks 4, 8, 12, and 12/early termination (ET). Results Data from 1025 patients were analyzed. At week 12/ET in both studies, patients who received peficitinib 100 mg or 150 mg reported significantly improved WPAI domain scores from baseline (except for absenteeism in RAJ4) compared with placebo (both doses, p<0.05). A higher proportion of peficitinib- versus placebo-treated patients achieved MCID in WPAI, HAQ-DI, SGAP, and PGA in studies RAJ3 and RAJ4. Significant differences with peficitinib versus placebo were evident in both studies as early as week 4 in HAQ-DI (peficitinib 150 mg only), SGAP, and PGA, and week 8 in WPAI loss of work productivity and daily activity impairment. At week 12/ET, significantly higher proportions of patients receiving peficitinib versus placebo achieved MCID in HAQ-DI, SGAP, PGA, and WPAI domains of presenteeism (RAJ3 only), loss of work productivity (RAJ3 only), and daily activity impairment (p<0.05 for all comparisons). Conclusions Peficitinib 100 mg or 150 mg administered daily over 12 weeks resulted in clinically meaningful improvements in outcomes that are important to RA patients, including pain, physical function, and work productivity and activity. These observations were reinforced through similar improvements in physicians’ rating of disease activity. Trial registration RAJ3: ClinicalTrials.gov, NCT02308163, registered 4 December 2014. RAJ4: ClinicalTrials.gov, NCT02305849, registered 3 December 2014.

show abstract

Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Cited by 13 publications

References 29 publications

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

Health‐related quality of life in rheumatoid arthritis: Systematic review and meta‐analysis of EuroQoL (EQ‐5D) utility scores from Asia

IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Contact Info

Product

Resources

About